ACTICOR BIOTECH SAS

Press Releases Acticor Biotech SAS

Equities

ALACT

FR0014005OJ5

End-of-day quote Euronext Paris Other stock markets 23:00:00 14/05/2024 BST			5-day change	1st Jan Change
1.14 ^EUR	+35.71%		+35.71%	-60.69%

05-15	Acticor: 'new perspectives' in stroke treatment	CF
04-30	Acticor Biotech SAS Announces Postponement in Publication of 2023 Annual Results	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024	05-15	BU
ACTICOR BIOTECH: Postponement of the Publication of Annual Results and Universal Registration Document 2023	04-30	BU
ACTICOR BIOTECH: Topline Results of ACTISAVE Phase 2/3 Study in Stroke Treatment	04-25	BU
Acticor Biotech will Present the Clinical Results of Its Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024	04-15	BU
Acticor Biotech Completes a Capital Increase for a Total Gross Amount of 8 Million Euros	03-15	BU
The University of Birmingham and Acticor Biotech announce the First Patient treated in LIBERATE, first clinical trial evaluating glenzocimab for heart attack	02-07	AQ
Acticor Biotech has just and timely completed patient recruitment of its phase 2/3 study in stroke	11-07	AQ
Acticor adapts its ACTISAVE clinical study to prepare the registration of glenzocimab for the treatment of stroke	14/09/23	AQ
Acticor Biotech SAS : Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022	27/04/22	PU
Acticor Biotech SAS : Inside Information / Other news releases	12/01/22	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer